Ligand Pharmaceuticals Incorporated (LGND) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)


Ligand Pharmaceuticals Incorporated's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ligand Pharmaceuticals Incorporated's ROI in the third quarter of 2026?
Ligand Pharmaceuticals Incorporated achieved a return on average invested assets (ROI) of 2.84 % in its third quarter of 2026, which is below Ligand Pharmaceuticals Incorporated's average return on investment, which stands at 13.99%.

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 91 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 692, from total ROI ranking in the second quarter of 2026 at 863.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 77.48 % 85.11 % 51.44 % 31.34 % 18.17 %
Y / Y Net Income Change TTM 5.93 % - - - -
Investment (TTM) in Millions 2,090 2,139 1,491 1,523 1,446
Return On Investment (TTM) 2.84 % 11.95 % 11.49 % 10.59 % 4.76 %
LGND's Overall Ranking # 692 # 863 # 1370 # 3129 # 3363
Seq. Investment Change TTM 9.75 % 23.49 % 13.72 % 15.15 % 14.48 %
Seq. Net Income Change TTM -73.91 % 28.43 % 23.39 % 156.18 % -
Net Income (TTM) in Millions 51 197 154 124 49

LGND Company Profile >> Back to LGND Roi Comparisons >> See Annual LGND Return On Investment



Return On Investment LGND's Ranking
Within: No.
Industry # 25
Sector # 92
Overall # 692

Return On Investment Statistics
High Average Low
73.91 %
13.99 %
-14.97 %
(Sep 30 2015)   (Mar 31 2025)







Financial Statements
Ligand Pharmaceuticals Incorporated's III. Quarter Investments $ 2,090 Millions LGND's Balance sheet
Ligand Pharmaceuticals Incorporated's III. Quarter Income $ -28 Millions Quarterly LGND's Income Statement
LGND's Income by Division See LGND's Income by Division


LGND Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,523 905 780 664 1,256
Y / Y Investment Growth 68.37 % 16.01 % 17.47 % -47.14 % -0.5 %
Net Income in Millions 124 -4 52 -33 57
Y / Y Net Income Growth - - - - -
Annual Return On Investment 8.17 % -0.45 % 6.69 % -5.03 % 4.55 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 8.17 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LGND's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LGND's Competitors
Subscribers only: Roi for Ligand Pharmaceuticals Incorporated's Suppliers
Subscribers only: Return On Investment for LGND's Customers

Other Ratios
LGND's Roa LGND's Inventory Turnover Ratio LGND's Growth Rates LGND's Dividend Statistics
LGND's Profitability Ratios LGND's Asset Turnover Ratio LGND's Dividend Growth
LGND's Roe LGND's Valuation Ratios LGND's Financial Strength Ratios LGND's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Ge Healthcare Technologies Inc   7.60 %
Incyte Corporation  6.81 %
Lifevantage Corp  6.51 %
Merit Medical Systems Inc  6.21 %
Davita Inc   6.13 %
Black Hawk Acquisition Corporation  6.10 %
Iqvia Holdings Inc   6.09 %
Labcorp Holdings Inc   6.07 %
Pacs Group Inc   5.95 %
Ensign Group Inc  5.94 %
Amneal Pharmaceuticals Inc   5.59 %
Sotera Health Company  5.43 %
Henry Schein Inc   5.27 %
Abbott Laboratories  5.14 %
Haemonetics Corporation  4.85 %
Teleflex Incorporated  4.81 %
Lifestance Health Group Inc   3.71 %
U S Physical Therapy Inc  3.33 %
Conmed Corporation  3.16 %
Integer Holdings Corporation  3.13 %
Avantor Inc   3.11 %
Innovage Holding Corp   2.95 %
Ligand Pharmaceuticals Incorporated  2.84 %
Revvity Inc  2.35 %
Pfizer Inc  2.34 %
Jazz Pharmaceuticals Plc  2.12 %
Teva Pharmaceutical Industries Limited  1.96 %
Icu Medical Inc  1.74 %
Biogen Inc   1.26 %
Community Health Systems Inc   1.03 %

Date modified: 2026-10-31T17:28:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.